Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Value and Efficacy of Transcranial Direct Current Stimulation in the Cognitive Rehabilitation: A Critical Review Since 2000.
The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vδ1 TCR.
Selective inhibition of CCR7- TEM cells activation by a novel peptide targeting Kv1.3 in a rat EAE model.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Monomethyl fumarate promotes Nrf2-dependent neuroprotection in retinal ischemia-reperfusion.
Elevation of Sema4A Implicates Th Cell Skewing and the Efficacy of IFN-β Therapy in Multiple Sclerosis.
Involvement of AMPK, IKβα-NFκB and eNOS in the sildenafil anti-inflammatory mechanism in a demyelination model.
ALSUntangled No. 8: Low dose naltrexone for ALS.
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
Increased Serum Brain-derived Neurotrophic Factor in Multiple Sclerosis Patients on Interferon-β and Its Impact on Functional Abilities.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
Nephrotic syndrome in multiple sclerosis patients who had undergone long-term interferon β-1b therapy.
National Cancer Institute Search for Clinical Trials
Santhera Announces Successful Outcome of Phase III Study with Catena®/Raxone® in Duchenne Muscular Dystrophy
European Medicines Agency
Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Thrombotic microangiopathy associated with interferon beta.
Treatment satisfaction, adherence and behavioral assessment in patients de - escalating from natalizumab to interferon beta.
GeNeuro Successful Phase 2a Clinical Study Reinforces Novel Approach to Treat Multiple Sclerosis: Patients Receiving First in Class GNbAC1 Mab Are Stable After One Year
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis

Pages